Vera Therapeutics Awaits FDA Decision on Atacicept for IgA Nephropathy
Event summary
- FDA granted priority review to atacicept BLA with a PDUFA date of July 7, 2026.
- Vera Therapeutics reported a net loss of $121.0 million for Q1 2026, up from $51.7 million in Q1 2025.
- Company has $596.8 million in cash and marketable securities as of March 31, 2026.
- Atacicept Phase 3 trial met primary endpoint with significant proteinuria reduction at week 36.
The big picture
Vera Therapeutics is on the cusp of a potential regulatory milestone with atacicept, a treatment for IgA Nephropathy. The company's strong cash position suggests it can fund operations through approval and beyond, but its significant Q1 2026 net loss highlights the financial pressures of bringing a novel therapy to market. The broader biotech sector is watching closely, as atacicept's success could set a precedent for targeting BAFF and APRIL in autoimmune diseases.
What we're watching
- Regulatory Approval
- Whether the FDA will grant accelerated approval for atacicept by the July 7, 2026 PDUFA date.
- Commercial Launch
- The pace at which Vera Therapeutics can execute a successful U.S. commercial launch of atacicept in mid-2026.
- Financial Sustainability
- How long Vera Therapeutics can sustain operations with its current cash position beyond the potential atacicept approval.
Related topics